January 2026 Research Update

This month, studies looking at daily treatment decisions in FMF painted a consistent picture: some people can remain without attacks after stopping colchicine, but this tended to happen in selected, milder situations, and silent inflammation could still increase. Separate studies focused less on whether biologics work and more on how they are used in practice, including how dosing is tapered and how adherence to colchicine can change once injections are started. Taken together, these studies add practical detail to the idea that FMF control is not only about choosing a medicine, but also about long-term follow-through and monitoring for inflammation even when symptoms are quiet. [1] [2] [3] [4]

In adults who voluntarily discontinued colchicine, remaining attack-free over the next year was uncommon and mostly seen in those who had already been attack-free for 6 months, had a milder pattern of FMF, and were not M694V homozygous. Even so, the study reported that CRP (a blood marker of inflammation) rose after stopping colchicine in both groups, suggesting that symptoms and inflammation did not always move together. The same study also reported that more frequent attacks before stopping predicted more attacks after stopping. [1]

In children with heterozygous MEFV mutations who stopped colchicine, many maintained drug-free remission, but relapse and restarting colchicine still occurred in a sizable minority. Outcomes differed by how the stopping decision happened: when discontinuation was physician-driven, patients had a longer symptom-free period before stopping and a lower risk of restarting compared with family/patient-driven stopping. Older age at discontinuation was also linked with staying in remission longer. [2]

A separate survey of rheumatologists described how biologic medicines are being used for colchicine-resistant FMF, most often choosing canakinumab, and commonly tapering by spreading out injection intervals rather than stopping abruptly. The same survey highlighted a real-world concern that many clinicians observe lower colchicine adherence after biologics are started, even though colchicine often remains part of care. This adds context that treatment success in practice may depend partly on shared expectations and routines around long-term medicines. [3]

One study in routine care connected adherence to colchicine with how people understand and feel about their illness. Higher illness-perception scores were linked with lower adherence, and specific areas such as feeling less personal control or finding the disease harder to understand were independent predictors of adherence differences. This helps explain why two people with similar symptoms might take colchicine differently over time. [4]

For patients and caregivers, this set of studies mainly adds understanding about what tends to happen when colchicine is stopped and why medication routines can be hard to maintain. The adult and pediatric discontinuation studies suggest that some people, especially those with a milder course and a longer symptom-free period beforehand, may have a better chance of staying attack-free, but inflammation markers can still rise and relapses can still occur. The survey and adherence study do not test which medicine is best, but they clarify that real-world issues like tapering plans and staying consistent with colchicine can strongly shape what living with FMF looks like over months and years. [1] [2] [3] [4]

What remains uncertain is how well these patterns apply to every person with FMF, because the discontinuation studies focused on specific groups (including selected children with heterozygous mutations and adults who chose to stop), and the survey reports clinician opinions rather than patient outcomes. Even with those limits, this month makes it clearer that being symptom-free does not always mean inflammation is fully quiet, and that understanding the illness and sticking with long-term routines are measurable parts of FMF care that researchers can track. [1] [2] [3] [4]

This month strengthened the message that FMF can affect more than attacks, with new data spanning long-term outcomes and early heart measurements. A nationwide follow-up study reported higher rates of several cardiovascular and kidney conditions in people with FMF than in matched controls, alongside persistently higher inflammation indices over time. Smaller heart-imaging studies did not focus on symptoms, but they reported measurable differences in heart chamber size and motion, and one study reported that some differences varied by MEFV mutation subtype. [5] [6] [7]

In a population-based cohort followed up to 20 years, FMF was linked with higher prevalence of ischemic heart disease, atrial fibrillation, stroke, heart failure, major adverse cardiovascular events, and kidney problems such as albuminuria and chronic kidney disease. The study also reported that inflammation-related blood indices stayed higher in FMF patients over time, even though traditional cardiometabolic risk factors were lower. In plain terms, this study suggests that long-term inflammation in FMF may go along with higher rates of certain heart and kidney diagnoses at the population level. [5]

Two smaller studies used detailed echocardiography to look for early or subtle heart differences. In one comparison of FMF patients on long-term colchicine versus healthy controls, pumping strength was preserved but the study reported thinner heart walls, larger left-ventricle chamber dimensions, and distinct left atrial strain patterns (how the atrium stretches and contracts). This kind of finding is not the same as having heart disease, but it suggests there may be measurable differences in heart mechanics in some people with FMF. [6]

A second echocardiography study reported that MEFV genotype groups differed in both clinical course and certain atrial strain measures. For example, M694V homozygotes had earlier onset, longer disease duration, higher disease activity scores, and reduced left atrial contractile strain compared with mutation-negative patients in that subgroup. This provides an early signal that genetic subtype may relate to subtle heart-function patterns, but it does not show who will develop symptoms or future heart disease. [7]

For patients, this month adds a clearer long-range picture: FMF was linked with higher rates of certain heart rhythm and blood-vessel conditions and kidney disease in a very large dataset, and smaller studies found subtle heart-function differences even when standard pumping measures were normal. Right now, the strongest part of this evidence is the population study showing higher diagnosed rates over time, while the imaging studies mainly add early research detail about how the heart may function differently in FMF. These results may matter most for longer-term understanding of health risks in FMF, rather than explaining day-to-day symptoms in any one person. [5] [6] [7]

What remains uncertain is how directly the subtle echocardiography differences connect to future symptoms or events, since these studies measured heart mechanics at a point in time. It is also not clear from these reports which individuals are most affected, because factors like disease activity and genetics vary widely. Even with those open questions, this month helps clarify that researchers are now measuring both long-term outcomes and earlier heart changes in FMF, which is a step toward understanding who may be at higher risk over many years. [5] [6] [7]

This month added several pieces about why FMF can look different from person to person, and why diagnosis is sometimes not straightforward. Blood and genetic studies pointed to immune and background genetic differences that might influence FMF risk or how the disease behaves, but they did not provide simple tests to track day-to-day disease activity. Case reports complemented this by showing that FMF can present in unexpected ways, including with symptoms outside the classic pattern and even when common MEFV mutation testing is negative. [8] [9] [10] [11]

One study measured IL-33, an immune signaling protein, and found numerically higher levels in FMF patients than in healthy controls, although the overall difference was not statistically significant. Levels were significantly higher in the colchicine-responsive subgroup. IL-33 did not consistently track with common inflammation tests or measures of disease activity, suggesting it may reflect an underlying immune pattern rather than a simple marker of whether the disease is flaring. In plain language, this points to IL-33 as a research clue about biology, not a reliable "flare meter" based on this study. [8]

Another study looked at HLA-B, a set of immune-system genetic markers, and reported that HLA-B*51 and HLA-B*35 were more frequent in FMF patients than in healthy controls, with HLA-B*27 modestly increased. HLA-B*44 was reported as more common in asymptomatic MEFV mutation carriers than in FMF patients, which could fit with the idea that background genes may shape whether someone develops symptoms. This kind of work does not diagnose FMF by itself, but it helps explain why people with similar MEFV mutations can have different experiences. [9]

The case reports showed that FMF may appear in less typical forms that can delay recognition. One report described a child with severe weight loss and recurrent fever who improved quickly after starting colchicine, despite negative targeted MEFV mutation testing, suggesting that genetic testing may not always capture every situation. Another report described recurrent pericarditis (inflammation around the heart) where MEFV testing later supported FMF as an underlying cause, shifting the explanation toward an autoinflammatory disease. [10] [11]

For patients and caregivers, these studies mainly affect understanding of variability in FMF rather than changing care right now. The IL-33 and HLA-B findings help explain that FMF biology involves more than a single gene or a single inflammation test, and that some immune markers may differ between subgroups such as colchicine-responsive versus colchicine-resistant patients. The case reports matter because they show that real people can have FMF with unusual symptoms or incomplete genetic confirmation, which can be important context for families navigating uncertainty around diagnosis. [8] [9] [10] [11]

What remains uncertain is whether IL-33 or HLA-B testing will ever be useful in routine FMF monitoring or prediction, since these studies did not show a clear link to disease activity or provide a way to forecast an individual course. Case reports also cannot show what will happen for most patients, but they can highlight gaps in current testing and the range of possible presentations. This month makes it clearer that FMF research is expanding beyond MEFV alone, while also underscoring that diagnosis can sometimes rely on the full clinical picture when tests are incomplete. [8] [9] [10] [11]

One study this month looked at whether IL-1 blocker treatment in FMF is linked with changes in hormone systems that affect energy, stress response, and reproduction. The main pattern was reassuring for major hormone axes: adrenal and thyroid-related results looked similar between those on IL-1 blockers and those on colchicine alone. At the same time, the study reported differences in a few other hormones, which may represent medication effects, underlying disease differences between groups, or measurement variation. [12]

In this cohort of adults treated for at least 6 months, ACTH, cortisol, and thyroid hormones did not differ meaningfully between the IL-1 antagonist group (anakinra or canakinumab) and the colchicine-only group, and testing in low-cortisol patients did not support adrenal insufficiency. The study did report lower FSH and GH and higher total testosterone in the IL-1 antagonist group compared with colchicine alone. Because the groups were not matched for age, sex, and disease severity, it is not clear how much of the difference was due to the medicines versus underlying differences between patients who needed IL-1 blockers. [12]

For patients using anakinra or canakinumab, this study mainly adds early reassurance that major adrenal and thyroid hormone problems were not seen in this cohort when compared with colchicine-only patients. The reported changes in GH, FSH, and testosterone are not enough to conclude a clear long-term effect, but they highlight areas researchers are watching as IL-1 blockers are used for longer periods. This information may matter more for longer-term understanding and future research than for immediate decision-making. [12]

What remains uncertain is whether these hormone differences would appear in other groups, such as children, people with different disease severity, or people followed for longer than 6 months, since this was a single-center study with imperfectly matched groups. The study still helps clarify that researchers are moving beyond symptom control alone and checking broader body systems that could affect quality of life. [12]

One paper this month looked at pregnancy outcomes after assisted reproductive technology (ART) across several immune-mediated rheumatic diseases, including FMF. The overall picture was mixed by disease: some conditions had clearly lower live birth rates per embryo transfer, while FMF had a relatively higher rate compared with the other diseases in this review. The authors emphasized that the certainty of evidence was very low to low, so the numbers should be seen as early estimates rather than firm predictions. [13]

Across 12 studies, the meta-analysis reported that live birth per embryo transfer was lower in Sjogren's syndrome and rheumatoid arthritis, while pooled live birth per embryo transfer in FMF was reported as 38%, the highest among the included diseases. The review also reported that live birth rates per couple were lower across immune-mediated rheumatic diseases as a group. Because the review noted possible confounding, it is not clear how much differences reflect the diseases themselves versus other factors such as age, medications, or fertility causes. [13]

For patients with FMF considering or using fertility treatments, this review adds cautious context rather than certainty. The main new point is that, within the limited published data included, FMF did not appear to have worse per-embryo-transfer live birth rates than other immune-mediated rheumatic diseases, and it was reported as the highest among them in this analysis. This is mainly research-level information for now because the evidence certainty was low and the included studies may differ in important ways. [13]

What remains uncertain is how well these pooled results predict an individual person's chances, since the review highlights confounding and the need for larger, higher-quality studies. Even with those uncertainties, this month helps clarify that FMF is being included in broader reproductive health research rather than being left out of the evidence base. [13]